FibroBiologics (FBLG) CSO Khoja Hamid Buys 298,508 Shares

What Happened

Khoja Hamid, Chief Scientific Officer of FibroBiologics, acquired 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 additional shares in a private placement on September 15, 2026. The combined purchase price for each share plus its accompanying warrant was $1.675, for a total cash payment of roughly $500,001. The Form 4 reports the equity line as an acquisition (transaction code A) and a separate derivative line for the warrants.

Key Details

• Transaction date: 2026-09-15 (filed same day)
• Shares purchased: 298,508 common shares
• Derivative acquired: Warrants to purchase up to 298,508 shares (one warrant per share)
• Price: Combined share + warrant price $1.675 each; total cash ≈ $500,001
• Warrant terms noted: Warrants are exercisable at any time until they expire (exercise price and expiry date not specified in the filing)
• Shares owned after transaction: Not specified in the Form 4
• Filing timeliness: Reported on the same day (no late filing flagged)
• Exhibit: Exhibit 24 — Power of Attorney included
• Transaction code: A = acquisition (purchase/award); derivative line records the warrants

Context

This was a private placement financing in which the insider purchased shares alongside warrants — a common way for companies to raise capital. The filing reflects an insider buy (an acquisition) rather than a sale or option exercise. Because the warrants' exercise price and expiry were not detailed in the Form 4 beyond being exercisable until they expire, investors should consult the company’s related disclosures (press release or private placement agreements) for full terms if that matters for valuation.